Page last updated: 2024-11-10

syringetin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID5281953
CHEMBL ID489142
CHEBI ID18215
SCHEMBL ID810981
MeSH IDM0542853

Synonyms (32)

Synonym
unii-j68jg79b9w
3,5,7-trihydroxy-2-(4-hydroxy-3,5-dimethoxyphenyl)-4h-1-benzopyran-4-one
j68jg79b9w ,
3',5'-dimethoxy-3,5,7,4'-tetrahydroxyflavone
4h-1-benzopyran-4-one, 3,5,7-trihydroxy-2-(4-hydroxy-3,5-dimethoxyphenyl)-
3,5,7-trihydroxy-2-(4-hydroxy-3,5-dimethoxyphenyl)-4h-chromen-4-one
CHEBI:18215 ,
syringetin ,
4423-37-4
3,5,7,4'-tetrahydroxy-3',5'-dimethoxyflavone
3',5'-o-dimethylmyricetin
CHEMBL489142
LMPK12112498
3,5,7-trihydroxy-2-(4-hydroxy-3,5-dimethoxyphenyl)chromen-4-one
3,5,7-trihydroxy-2-(4-hydroxy-3,5-dimethoxy-phenyl)chromen-4-one
FT-0635283
SCHEMBL810981
mfcd00017449
UZMAPBJVXOGOFT-UHFFFAOYSA-N
myricetin-3',5'-dimethyl ether
DTXSID60196074
AKOS030530648
bdbm50025603
Q3509026
MS-25319
E88713
CS-0149371
diboa trihexose
HY-N8920
3,5-dimethoxy-3,5,7,4-tetrahydroxyflavone
flavone, 3,4,5,7-tetrahydroxy-3,5-dimethoxy-
myricetin-3,5-dimethyl ether
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
platelet aggregation inhibitorA drug or agent which antagonizes or impairs any mechanism leading to blood platelet aggregation, whether during the phases of activation and shape change or following the dense-granule release reaction and stimulation of the prostaglandin-thromboxane system.
metaboliteAny intermediate or product resulting from metabolism. The term 'metabolite' subsumes the classes commonly known as primary and secondary metabolites.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (5)

ClassDescription
tetrahydroxyflavoneAny hydroxyflavone carrying four hydroxy substituents.
dimethoxyflavoneAny methoxyflavone with two methoxy substituents.
7-hydroxyflavonolAny flavonol carrying a 7-hydroxy substituent.
3'-methoxyflavonesAny methoxyflavone with a methoxy substituent at position 3'.
3',5'-dimethoxyflavoneA dimethoxyflavone in which the hydroxy groups at positions 3' and 5' have been replaced by methoxy groups.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (8)

Assay IDTitleYearJournalArticle
AID439368Agonist activity at human PPARgamma expressed in HEK293 cells co-transfected with PPRE assessed as beta-galactosidase signal at 25 uM after 48 hrs by reporter gene assay relative to control2009Journal of medicinal chemistry, Nov-12, Volume: 52, Issue:21
7-Hydroxy-benzopyran-4-one derivatives: a novel pharmacophore of peroxisome proliferator-activated receptor alpha and -gamma (PPARalpha and gamma) dual agonists.
AID658255Cytotoxicity against human Huh7.5.1 cells by MTT assay2012European journal of medicinal chemistry, Jun, Volume: 52Discovery of flavonoid derivatives as anti-HCV agents via pharmacophore search combining molecular docking strategy.
AID1434690Inhibition of sucrose loaded POPC/POPE/POPS/PtdIns(3,4,5)P3 (59:20:20:1) liposome binding to eGFP-fused PDK1 PH domain (unknown origin) expressed in Escherichia coli BL21 at 20 uM after 10 mins by fluorescence spectrophotometry based pull down assay relat2017Bioorganic & medicinal chemistry letters, 02-01, Volume: 27, Issue:3
Inhibitory potential of flavonoids on PtdIns(3,4,5)P3 binding with the phosphoinositide-dependent kinase 1 pleckstrin homology domain.
AID400608Inhibition of procoagulant activity in monocyte from human blood assessed as counteraction of IL1-induced tissue factor expression after 18 hrs1996Journal of natural products, Mar, Volume: 59, Issue:3
Ability of different flavonoids to inhibit the procoagulant activity of adherent human monocytes.
AID439367Agonist activity at human PPARgamma expressed in HEK293 cells co-transfected with PPRE assessed as beta-galactosidase signal at 5 uM after 48 hrs by reporter gene assay relative to control2009Journal of medicinal chemistry, Nov-12, Volume: 52, Issue:21
7-Hydroxy-benzopyran-4-one derivatives: a novel pharmacophore of peroxisome proliferator-activated receptor alpha and -gamma (PPARalpha and gamma) dual agonists.
AID658253Antiviral activity against HCV JFH-1 J399EM infected in Human Huh7.5.1 cells assessed as suppression of viral replication after 72 hrs by EGFP assay2012European journal of medicinal chemistry, Jun, Volume: 52Discovery of flavonoid derivatives as anti-HCV agents via pharmacophore search combining molecular docking strategy.
AID338750Inhibition of bovine thymus p56LCK-catalyzed phosphorylation of angiotensin 1 by SDS-PAGE
AID358174Inhibition of p56 lck1992Journal of natural products, Nov, Volume: 55, Issue:11
Protein-tyrosine kinase inhibition: mechanism-based discovery of antitumor agents.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (12)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's2 (16.67)18.2507
2000's2 (16.67)29.6817
2010's6 (50.00)24.3611
2020's2 (16.67)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 25.72

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index25.72 (24.57)
Research Supply Index2.64 (2.92)
Research Growth Index5.03 (4.65)
Search Engine Demand Index26.67 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (25.72)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (7.69%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other12 (92.31%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]